All Primary Antibodies
Primary antibodies, immunoglobulins that bind to specific proteins or other biomolecules, are used in many research applications and protocols to detect targets of interest. They are developed using different animal hosts, including mouse, rat, rabbit, goat, sheep, and many others.
Monoclonal and Polyclonal Antibodies
One type of primary antibodies, monoclonal antibodies, provides high reproducibility and low cross-reactivity and background noise. Another type, polyclonal antibodies, often costs less and provides greater affinity and quicker binding. Both are produced using plasma B cells, but the former uses the same clone and the latter uses different clones. Monoclonal antibodies require hybridoma cell lines, and polyclonal antibodies do not.
There are also recombinant monoclonal antibodies with similar benefits, like high affinity, scalability, and specificity. They are produced using in vitro cloning of plasma B cells and expression hosts.
Conjugated Primary Antibodies
Antibodies can be labeled with various fluorophores or detection agents or used without labels. Labeled primary antibodies, also known as conjugated primary antibodies, help researchers simplify and streamline their applications. They are coupled with common enzymes and dyes such as Alexa Fluor and often used in protein and cell analysis.
Applications
Antibodies for life sciences applications are used in flow cytometry, western blotting, ELISA, immunohistochemistry, and immunocytochemistry. Secondary antibodies can be added to support the detection and purification of certain antigens. They bind to the primary antibody, which binds to the antigen of interest. Finding the right combination of antibodies can result in greater antigen specificity and a strong, detectable signal.
- (40)
- (149)
- (22)
- (22)
- (22)
- (488)
- (47)
- (57)
- (28)
- (172)
- (306)
- (31)
- (219)
- (61)
- (2)
- (7)
- (7)
- (3)
- (2)
- (183)
- (615)
- (41)
- (28)
- (23)
- (6)
- (1)
- (14)
- (16)
- (16)
- (14)
- (13)
- (17)
- (16)
- (14)
- (25)
- (21)
- (18)
- (18)
- (18)
- (15)
- (18)
- (17)
- (19)
- (18)
- (29)
- (18)
- (9)
- (18)
- (6)
- (6)
- (18)
- (8)
- (28)
- (6)
- (7)
- (6)
- (16)
- (1)
- (2)
- (1)
- (119)
- (16)
- (18)
- (15)
- (182)
- (60)
- (108)
- (112)
- (13)
- (38)
- (40)
- (96)
- (22)
- (1)
- (12)
- (7)
- (1)
- (4)
- (1)
- (514)
- (19)
- (2)
- (1)
- (4)
- (18)
- (41)
- (26)
- (3)
- (1)
- (1)
- (3)
- (2)
- (7)
- (8)
- (2)
- (2)
- (11)
- (2)
- (2)
- (2)
Filtered Search Results
| Content And Storage | Store at 4C. |
|---|---|
| Target Species | Human,Mouse,Rat |
| Host Species | Mouse |
| Conjugate | Unconjugated |
| Applications | Immunohistochemistry (Paraffin),Immunofluorescence |
| Form | Purified |
| Isotype | IgM κ |
| Concentration | 0.2 mg/mL |
| Antigen | Thomsen-Friedenreich Antigen |
| Regulatory Status | RUO |
| Purification Method | Protein A or G purified |
| Dilution | Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml |
| Formulation | 10mM PBS and 0.05% BSA with 0.05% Sodium Azide |
| Immunogen | Neuraminidase-treated human red blood cells |
| Classification | Monoclonal |
| Primary or Secondary | Primary |
| Test Specificity | Recognizes a disaccharide epitope, Gal1-3GalNAc, of Thomsen-Friedenreich (TF) antigen. It is specific for both anomeric forms of the disaccharide (TF and TF, including related structures on the glycolipid) and shows no cross-reactivity with sialylated glycophorin. The Thomsen-Friedenreich antigen acts as an oncofetal antigen, with low expression in normal adult tissues but increasing to fetal levels of expression in hyperplasia or malignancy. It is considered as a pan-carcinoma marker. This MAb is capable to agglutinate desialylated red blood cells. During metastasis, the ability of malignant cells to form multicellular aggregates via homotypic or heterotypic aggregation and their adhesion to the endothelium are critical. The tumor-associated carbohydrate Thomsen-Friedenreich antigen (Gal-GalNAc) is involved in tumor cell adhesion and tissue invasion. It also causes an immune response, and overexpression of the antigen causes cancer cells to be more sensitive to natural killer cell lysis. The Thomsen-Friedenreich antigen is suppressed in normal healthy cells and represents one of the few chemically well-defined antigens associated with tumor malignancy. The presence of the Thomsen-Friedenreich antigen on the surface of cancer cells may result from a divergence from the normal pathway for O-linked glycosylation in these cells, most likely caused by inappropriate localization of the enzymes involved in synthesis of the disaccharide. |
| Clone | SPM320 |
| Content And Storage | Store at 4C. |
|---|---|
| Target Species | Human,Mouse,Rat |
| Host Species | Mouse |
| Conjugate | Unconjugated |
| Applications | Immunohistochemistry (Paraffin),Immunofluorescence |
| Form | Purified |
| Isotype | IgM κ |
| Concentration | 0.2 mg/mL |
| Antigen | Thomsen-Friedenreich Antigen |
| Regulatory Status | RUO |
| Purification Method | Protein A or G purified |
| Dilution | Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml |
| Formulation | 10mM PBS and 0.05% BSA with 0.05% Sodium Azide |
| Immunogen | Neuraminidase-treated human red blood cells |
| Classification | Monoclonal |
| Primary or Secondary | Primary |
| Test Specificity | Recognizes a disaccharide epitope, Gal1-3GalNAc, of Thomsen-Friedenreich (TF) antigen. It is specific for both anomeric forms of the disaccharide (TF and TF, including related structures on the glycolipid) and shows no cross-reactivity with sialylated glycophorin. The Thomsen-Friedenreich antigen acts as an oncofetal antigen, with low expression in normal adult tissues but increasing to fetal levels of expression in hyperplasia or malignancy. It is considered as a pan-carcinoma marker. This MAb is capable to agglutinate desialylated red blood cells. During metastasis, the ability of malignant cells to form multicellular aggregates via homotypic or heterotypic aggregation and their adhesion to the endothelium are critical. The tumor-associated carbohydrate Thomsen-Friedenreich antigen (Gal-GalNAc) is involved in tumor cell adhesion and tissue invasion. It also causes an immune response, and overexpression of the antigen causes cancer cells to be more sensitive to natural killer cell lysis. The Thomsen-Friedenreich antigen is suppressed in normal healthy cells and represents one of the few chemically well-defined antigens associated with tumor malignancy. The presence of the Thomsen-Friedenreich antigen on the surface of cancer cells may result from a divergence from the normal pathway for O-linked glycosylation in these cells, most likely caused by inappropriate localization of the enzymes involved in synthesis of the disaccharide. |
| Clone | A68-B/A11 |